||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Levrett Share Discussion Threads
Showing 126 to 150 of 150 messages
Im sure it will go ahead.|
Assuming that the RTO takes place, my expectation is that the existing no of LVRT shares will be increased substantially but with current LVRT shareholders benefiting from the new shares in proportion to their current holdings.
Hopefully the value of the new shares will mean that existing LVRT shareholders see gains from the RTO but given that the new shares will be traded on AIM, there can be no guarantees about share price until trading commences and prospective new investors have been able
to consider the prospectus and other info on the new co.
Presumably the new co will have an new name and its shares a new EPIC.
All the above is subject to the RTO going ahead and is imho!|
|Maytrees-do you think we will have the same amount of shares on admission or an exchange like 2/1 exchange?|
|Is that losers or loosers you fool.|
|Nothing wrong with Corvus? It backs loosers - just look at the track record...|
|This is a corvus shell in biotech.
Im sure the new company will be guided by industry professionals so very little input from corvus
Nothing wrong with corvus.|
|Sirius - are you having a laugh? ASOS was 20 years ago! Name the "many others" (there aren't any!).|
|Asos, sirius amongst many others fred|
Suggest here that nuformix is a thalesnano spin off|
|What winners have Corvus promoted? Gable, Conival, Mentum, Gaming Insight, diamond Tech - all went bust!|
|Not all become winners but most corvus companys do.
Anthony reeves had little say over cloudtag imo|
LVRT shares have been suspended from trading since September 2016 pending RTO. A little difficult for those holding since then to do much else or avoid as you suggest at this time!
Shortly before the LVRT suspension the share price soared N which emabled holders to take some good profits.
Cant speak about CTAG though.|
|Anthony Reeves is a director of LVRT and also of CTAG.AVOID.|
|Good morning all
The company situation is quite different of course but it would be nice for LVRT to have the same (currently) 400% share price gain
being enjoyed by RLH holders at present.
I think RLH is a shell co though its suspension arose not from an RTO possibility but from
|At least you found out either way after 9 months.|
try 14 months so far in SILF.
wait another 8-10 months and youre probably getting close!|
|Good morning jimduggan
From looking at the website it appeared to me that the comment was new or at least post-16th September 2016.
The RTO seems still seems live despite the long wait.|
|Yes we are all aware of that
All we need is the readmission documents and meeting date|
|The LVRT website states:
Further to the announcement dated 16 September 2016 relating to the possible acquisition of Nuformix Limited, the Company can confirm that the Acquisition is at an advanced stage, subject to the completion of documentation and compliance with all regulatory requirements.
The Company intends to convene a General Meeting in order to seek the shareholder approvals necessary to pursue this opportunity, following publication of the prospectus. Further announcements to shareholders will be made in due course.|
|First 2 reformulated products to enter clinical development are in oncology!!!
Chris gooding from nuformix feb 2017
Clare Sansom reports from Nano World Cancer Day: London 2017 Dr Dan Gooding of Nuformix, a ‘micro-SME’ based in Cambridge, UK, described a novel method of re-purposing known small-molecule drugs including oncology drugs by re-engineering their crystalline forms. Crystallising a pharmaceutically active compound with a second, inert and non-toxic one will produce a substance with identical pharmacology but very different physical properties. These new physical properties can uniquely enable the creation of new drug products, for example in new delivery formats, in new indications or for new geographic markets. Regulatory agencies can rely on existing safety data to support future product approvals unlike in the case of novel chemical entities, enabling products containing cocrystal forms of known drugs to move more rapidly towards patients and the market. Crucially, the alterations to the drug substance are significant enough to be protected with new ‘substance of matter’ patents. Two of Nuformix’ first three re-formulated products to enter clinical development are in oncology.|
Indeed i am sure that it will all turn out prosperous for all but the long delay and lack of funds in my trading account is quite frustrating.|
The LSE board poster (see above) knows as much or as little as the rest of us!
The delay imho is positive as if the two companies had proved incompatible, one would
have expected a suitably worded announcement to that effect to have been made by now.|
|Ummmm yes that is at least a positive|